Product Details

Verodut Capsules meet Indian Pharmacopoeia (IP) standards for the management of benign prostatic hyperplasia. Specifically, each capsule delivers Dutasteride IP at 0.5mg. As a result, it offers effective long-term reduction of prostate volume and improvement of urinary symptoms in men with an enlarged prostate.

The capsules contain:

• Dutasteride IP (0.5mg) – A dual 5-alpha reductase inhibitor that blocks the conversion of testosterone to dihydrotestosterone (DHT). Consequently, it reduces prostate volume over time, easing urinary obstruction and lowering the risk of acute urinary retention and the need for prostate-related surgery.

Physicians prescribe Verodut for the long-term management of benign prostatic hyperplasia (BPH) in men with an enlarged prostate, either alone or in combination with alpha-blocker therapy. In addition, its once-daily oral dosing supports simple, sustainable long-term treatment. Because of this profile, Verodut suits urology practices and general physicians managing chronic BPH symptoms.

Key Features:

• Overall, this IP-compliant formulation guarantees pharmaceutical-grade purity
• Additionally, the oral capsule format supports easy, once-daily dosing
• Furthermore, each capsule delivers precise, validated dosage accuracy at 0.5mg
• Notably, rigorous quality testing backs every stage of manufacturing
• Beyond that, blister packaging protects capsule integrity against light
• Ultimately, a reliable supply chain suits bulk distribution to hospitals, clinics, and pharmacies